StreetInsider.com News Articles

Monte Rosa Therapeutics (GLUE) PT Raised to $19 at UBS

Mon, 12 Oct 2026 08:52:37 -0400

UBS analyst Alice Nettleton raised the price target on Monte Rosa Therapeutics (NASDAQ: GLUE) to $19.00 (from $17.00) while maintaining a Buy rating.

Form 4 Monte Rosa Therapeutics, For: Oct 05 Filed by: Bowen Matthew

Tue, 06 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261006/27155450.html

H.C. Wainwright Reiterates Buy Rating on Monte Rosa Therapeutics (GLUE)

Mon, 05 Oct 2026 06:43:01 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $25.00 price target on Monte Rosa Therapeutics (NASDAQ: GLUE).

The analyst commented: "MRT-8102 cleared our lower-dose bar, supporting the gout and HS programs that contribute ~$15 of our $25 price target. Monte Rosa’s October 1 GFORCE-1 update reported median high sensitivity C-reactive protein (hsCRP) reductions of 86%, 79%, and 85% at 5mg, 20mg, and 40mg daily, respectively, after four weeks in a 108-participant randomized study. The 5mg result exceeded our preferred ~80-85% suppression benchmark, with no AE-related discontinuations at that dose. This supports testing lower doses in longer patient studies

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to five newly hired non-executive employees as a material inducement to commencing their employment with the Company.

The employees received, in the aggregate, non-qualified stock options to purchase 86,725 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $11.26 as reported by Nasdaq on October 1, the effective date of the grant

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

Form 8-K Monte Rosa Therapeutics, For: Oct 01

Thu, 01 Oct 2026 07:38:00 -0400

si-local-file:///var/storage/secattach/20261001/27131632.html

Monte Rosa reports Phase 1 data for MRT-8102 in cardiovascular study

Thu, 01 Oct 2026 07:00:15 -0400

Monte Rosa Therapeutics (Nasdaq: GLUE) announced results from its GFORCE-1 Phase 1 study evaluating MRT-8102, a NEK7-directed molecular glue degrader, in 108 obese subjects with elevated cardiovascular disease risk.

The study randomized participants to once-daily doses of 5 mg, 20 mg, or 40 mg of MRT-8102, or placebo, over four weeks, followed by four weeks of safety follow-up. The drug achieved median NEK7 degradation of approximately 80% to 90% across all three dose levels.

Key biomarker reductions reported included calprotectin (56%), S100A12 (46%), SAA (51%), IL-6 (54%), and hsCRP (85%). HMGB1 and IL-1β were reduced by a median of 40% and 37%,

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

Thu, 01 Oct 2026 07:00:00 -0400

In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis, and systemic inflammation

Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses

HMGB1, calprotectin, S100A12, and SAA, damage-associated molecular patterns (DAMPs) linked to atherosclerotic plaque progression and instability, and IL-1β, all established key pathogenic drivers of ASCVD, were reduced to levels comparable

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

Thu, 01 Oct 2026 07:00:00 -0400

In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis, and systemic inflammation

Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses

HMGB1, calprotectin, S100A12, and SAA, damage-associated molecular patterns (DAMPs) linked to atherosclerotic plaque progression and instability, and IL-1β, all established key pathogenic drivers of ASCVD, were reduced to levels comparable

H.C. Wainwright Starts Monte Rosa Therapeutics (GLUE) at Buy

Thu, 01 Oct 2026 06:07:42 -0400

H.C. Wainwright analyst Mitchell S. Kapoor initiates coverage on Monte Rosa Therapeutics (NASDAQ: GLUE) with a Buy rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Monte Rosa Therapeutics click here. For more ratings news on Monte Rosa Therapeutics click here.
Shares of Monte Rosa Therapeutics closed at $11.93 yesterday.

Monte Rosa to share Phase 1 MRT-8102 cardiovascular study data

Wed, 30 Sep 2026 16:01:07 -0400

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced it will host a conference call and webcast on Oct. 1, 2026, at 8:00 a.m. ET to present clinical results from its GFORCE-1 Phase 1 study of MRT-8102.

MRT-8102 is a NEK7-directed molecular glue degrader being studied in subjects with elevated cardiovascular disease risk. The presentation will include safety and activity data across multiple dose levels following four weeks of treatment, along with data on the modulation of multiple pathogenic drivers of atherosclerotic cardiovascular disease.

An archived version of the webcast will be available for 30 days following the presentation, according to a press release

Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

Wed, 30 Sep 2026 16:01:00 -0400

Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk. The presentation will include safety and activity data for MRT-8102 across multiple dose

Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

Wed, 30 Sep 2026 16:01:00 -0400

Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk. The presentation will include safety and activity data for MRT-8102 across multiple dose

Novartis starts Phase 2 trial for Monte Rosa drug, triggering $50M payment

Tue, 08 Sep 2026 07:00:21 -0400

Monte Rosa Therapeutics (Nasdaq: GLUE) announced that Novartis has initiated a Phase 2 clinical study for MRT-6160 (DDY391), a VAV1-directed molecular glue degrader, in participants with Sjögren's disease. The milestone triggers a $50 million payment to Monte Rosa from Novartis.

The study is a Phase 2a/b, randomized, double-blind, placebo-controlled, multi-center trial evaluating the efficacy, safety, and tolerability of up to 52 weeks of treatment with MRT-6160 (DDY391). The trial is listed on ClinicalTrials.gov under identifier NCT07737743.

Novartis holds exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 molecular glue degraders under a global exclusive license agreement with Monte Rosa.

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Tue, 08 Sep 2026 07:00:00 -0400

Phase 2 study to be conducted in participants with Sjögren’s disease

Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa

Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study

Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Tue, 08 Sep 2026 07:00:00 -0400

Phase 2 study to be conducted in participants with Sjögren’s disease

Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa

Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study

Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:01:00 -0400

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to six newly hired non-executive employees as a material inducement to commencing their employment with the Company.

The employees received, in the aggregate, non-qualified stock options to purchase 31,145 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $14.31 as reported by Nasdaq on September 1, the effective date of the grant

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:01:00 -0400

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to six newly hired non-executive employees as a material inducement to commencing their employment with the Company.

The employees received, in the aggregate, non-qualified stock options to purchase 31,145 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $14.31 as reported by Nasdaq on September 1, the effective date of the grant

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.
The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for